You are here: Home > Our Business > Areas of Focus

Areas of Focus

1415256989135382.jpgAt CanSinoBIO’s our main research and development focus is vaccines.  

To this end, we apply our expertise across a range  targets from antigen

discovery, antigen overexpression, purification and formulation to

proof-of-concept pre-clinical evaluation, production process

development and assay development.

 

Our team works with world’s most advanced equipment and lab resources   

for microbiology, molecular  cell biology, immunology and biochemistry.  

We also maintain top- notch animal research facilities.  Working alone and

with partners, CanSinoBIO’s R&D team has nurtured  a strong developmental

pipeline over the years. We have an impressive array of  vaccine candidates

currently undergoing pre-clinical studies including  recombinant protein-based

pneumococcal vaccines, adenovirus-based recombinant TB vaccines, and

polyvalent conjugate vaccines. Along with these , we have also developed novel

carrier proteins and other viral vector-based new vaccine candidates. A number

of vaccine-producing bacterial strains have also been engineered by us using

recombinant technologies, and these strains allow us to accomplish exceptionally

high vaccine yields while  simplifying overall manufacturing  processes.  For

example, our component pertussis vaccine has already advanced into the

scaled-up production phase, and  has been proven  to outperform  our peers in

both quality and productivity. Additionally, it was our construction of a genetically

detoxified diphtheria toxoid CRM197-overexpressing corynebacterium diphtheria

strain that brought about a  industry technical breakthrough in carrier protein

production.